Enhanced monitoring and detection of recent genotype 3 hepatitis E virus infection through urine antigen testing.
Journal Information
Full Title: Emerg Microbes Infect
Abbreviation: Emerg Microbes Infect
Country: Unknown
Publisher: Unknown
Language: N/A
Publication Details
Subject Category: Communicable Diseases
Available in Europe PMC: Yes
Available in PMC: Yes
PDF Available: No
Related Papers from Same Journal
Transparency Score
Transparency Indicators
Click on green indicators to view evidence textCore Indicators
"Disclosure statement BM: funding: Altona Diagnostics, Roche, Fujirebio; consulting: Roche; lectures: Roche, Fujirebio; HW: clinical trials: Abbvie, Altimmune, Bristol-Myers-Squibb, Gilead, Janssen, MYR GmbH, Novartis, Vir Biotechnology; grants: Abbvie, Biotest AG, Gilead; consulting or advisory board: Abbvie, Aligos Therapeutics, Altimmune, Biotest AG, Bristol-Myers-Squibb, BTG pharmaceuticals, Dicerna Pharmaceuticals, Enanta Pharmaceuticals, Gilead, Janssen, Merck KGaA, MYR GmbH, Roche, Vir Biotechnology; lectures: Falk Foundation, Gilead, Merck KGaA. YS, IK, HH, BB, HHJS, TP, BS and PB have nothing to declare."
"Disclosure statement: BM: funding: Altona Diagnostics, Roche, Fujirebio; consulting: Roche; lectures: Roche, Fujirebio; HW: clinical trials: Abbvie, Altimmune, Bristol-Myers-Squibb, Gilead, Janssen, MYR GmbH, Novartis, Vir Biotechnology; grants: Abbvie, Biotest AG, Gilead; consulting or advisory board: Abbvie, Aligos Therapeutics, Altimmune, Biotest AG, Bristol-Myers-Squibb, BTG pharmaceuticals, Dicerna Pharmaceuticals, Enanta Pharmaceuticals, Gilead, Janssen, Merck KGaA, MYR GmbH, Roche, Vir Biotechnology; lectures: Falk Foundation, Gilead, Merck KGaA. YS, IK, HH, BB, HHJS, TP, BS and PB have nothing to declare."
Additional Indicators
Assessment Info
Tool: rtransparent
OST Version: N/A
Last Updated: Aug 05, 2025